Gut Metabolite Boosts HIV Therapy in Monkeys

According to researchers at UC Davis Health, microbial metabolite 10-hydroxystearic acid (10-HSA) rapidly repairs gut epithelial barrier structure and function in primate models, addressing persistent inflammation that survives standard antiretroviral therapy for HIV. Worldwide, an estimated 40.9 million people lived with HIV in 2025, alongside approximately 1.2 million new infections and 570,000 AIDS-related deaths, according to public health data.

Gut Damage and HIV Persistence in Patients

Gut-associated lymphoid tissue serves as an early target during HIV infection, according to study findings published in Nature Microbiology. The virus damages immune and epithelial cells within the intestinal lining, which triggers an inflamed and leaky gut, a weakened immune defense, reduced nutrient absorption, and disrupted mitochondrial function.

Even when patients maintain strict adherence to antiretroviral therapy (ART), many still experience persistent gut inflammation driven by the virus. Previous research indicated that the common bacterium Lactiplantibacillus plantarum—found in fermented foods, over-the-counter probiotics, and the human digestive tract—might help heal this chronic condition.

Identification of 10-HSA and PPAR-Alpha Activation

Researchers identified metabolites produced by L. plantarum inside the virally inflamed gut environment of non-human primate models. Out of hundreds of molecules created by the bacterium, 10-HSA emerged as the strongest candidate for repairing the gut barrier and lowering inflammation.

“Current HIV therapies are remarkably effective at controlling viral replication, but they do not fully repair the profound damage HIV causes in the gut,” said Satya Dandekar, PhD, professor in the Department of Medical Microbiology and Immunology at UC Davis Health. “Our findings suggest that restoring the gut’s structural and immune health can enhance antiretroviral treatment and opens an entirely new avenue for achieving more durable control of HIV.”

Primate Model Results for 10-HSA and ART Combination

The research team conducted two independent studies at the UC Davis National Biomedical Research Institute using non-human primates infected with simian immunodeficiency virus (SIV). The first trial evaluated 10-HSA independently without ART, resulting in intestinal repair, improved key markers of gut function, better mitochondrial health, decreased inflammatory signaling, and a partial restoration of the gut microbiota.

When researchers administered 10-HSA alongside ART, the combination treatment achieved faster clearance of viral burden than ART alone. This combined approach also accelerated the recovery of gut immune cells, lowered immune activation, and reestablished epithelial barrier integrity alongside beneficial gut microbiota and microbial diversity.

“The findings suggest repairing the tissue damage caused by HIV may be as important as suppressing the virus itself with antiretroviral therapy,” said Dylan Kramer, PhD, a recent graduate from the Dandekar Lab. “By rebuilding the gut barrier, restoring mitochondrial function and reducing inflammation, 10-HSA helps create conditions that support stronger immune recovery and more effective antiviral therapy for HIV.”

Study authors emphasize that these results derive exclusively from preclinical models, though the tests showed no adverse effects. These outcomes support advancing toward safety and effectiveness testing of 10-HSA in humans.

Dandekar noted that treating the damaged gut ecosystem aids immune system recovery, helping patients regain functions lost during infection. Furthermore, restoring gut barrier integrity and microbial balance via 10-HSA supplementation may represent a promising therapeutic strategy that may extend past HIV to treat other chronic inflammatory diseases of the gastrointestinal tract.

Frequently Asked Questions

What is 10-hydroxystearic acid (10-HSA)?

10-HSA is a microbial metabolite produced by the bacterium Lactiplantibacillus plantarum that repairs gut epithelial barrier damage and reduces inflammation.

How does 10-HSA interact with the body?

X-ray crystallography shows that 10-HSA binds directly to PPAR-alpha, a nuclear receptor, which promotes inducing lipid metabolism, mitochondrial regeneration, and gut epithelial renewal.

Has 10-HSA been tested in humans?

Current results stem from preclinical models, but researchers indicate the safety and effectiveness data support moving forward with human clinical testing.